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Recommended Immunization Schedules for Persons Aged 0 Through 18 Years—UNITED STATES, 2016 
The Recommended Immunization Schedules for 
Persons Aged 0 Through 18 Years are approved by the 
Advisory Committee on Immunization Practices 
(http://www.cdc.gov/vaccines/acip)
American Academy of Pediatrics 
(http://www.aap.org)
American Academy of Family Physicians 
(http://www.aafp.org)
American College of Obstetricians and Gynecologists
(http://www.acog.org)
This schedule includes recommendations in effect as of January 1, 2016. Any dose not administered at the recommended age should be 
administered at a subsequent visit, when indicated and feasible. The use of a combination vaccine generally is preferred over separate injections 
of its equivalent component vaccines. Vaccination providers should consult the relevant Advisory Committee on Immunization Practices (ACIP) 
statement for detailed recommendations, available online at http://www.cdc.gov/vaccines/hcp/acip-recs/index.html. Clinically significant adverse 
events that follow vaccination should be reported to the Vaccine Adverse Event Reporting System (VAERS) online (http://www.vaers.hhs.gov) or by 
telephone (800-822-7967).
Figure 1. Recommended immunization schedule for persons aged 0 through 18 years – United States, 2016. (FOR THOSE WHO FALL BEHIND OR START LATE, SEE THE CATCH-UP SCHEDULE [FIGURE 2]). 
These recommendations must be read with the footnotes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars in Figure 1. To determine minimum intervals 
between doses, see the catch-up schedule (Figure 2). School entry and adolescent vaccine age groups are shaded.
NOTE: The above recommendations must be read along with the footnotes of this schedule. 
This schedule includes recommendations in effect as of January 1, 2016. Any dose not administered at the recommended age should be administered at a subsequent visit, when indicated and feasible. The use of a combination vaccine generally is preferred 
over separate injections of its equivalent component vaccines. Vaccination providers should consult the relevant Advisory Committee on Immunization Practices (ACIP) statement for detailed recommendations, available online at http://www.cdc.gov/vaccines/
hcp/acip-recs/index.html. Clinically significant adverse events that follow vaccination should be reported to the Vaccine Adverse Event Reporting System (VAERS) online (http://www.vaers.hhs.gov) or by telephone (800-822-7967). Suspected cases of vaccine-
preventable diseases should be reported to the state or local health department. Additional information, including precautions and contraindications for vaccination, is available from CDC online (http://www.cdc.gov/vaccines/recs/vac-admin/contraindications.
htm) or by telephone (800-CDC-INFO [800-232-4636]).
This schedule is approved by the Advisory Committee on Immunization Practices (http//www.cdc.gov/vaccines/acip), the American Academy of Pediatrics (http://www.aap.org), the American Academy of Family Physicians (http://www.aafp.org), and the 
American College of Obstetricians and Gynecologists (http://www.acog.org).
Vaccine Birth 1 mo 2 mos 4 mos 6 mos 9 mos 12 mos 15 mos 18 mos 19–23 mos 2-3 yrs 4-6 yrs 7-10 yrs 11-12 yrs 13–15 yrs 16–18 yrs
Hepatitis B1  (HepB)
Rotavirus2  (RV) RV1 (2-dose series); RV5 (3-dose series)
Diphtheria, tetanus, & acellular pertussis3  (DTaP: <7 yrs)
Haemophilus influenzae type b4  (Hib)
Pneumococcal conjugate5  (PCV13)
Inactivated poliovirus6  (IPV: <18 yrs)
Influenza7  (IIV; LAIV) 
Measles, mumps, rubella8  (MMR)
Varicella9  (VAR)
Hepatitis A1 0  (HepA) 
Meningococcal1 1  (Hib-MenCY  
> 6 weeks; MenACWY-D >9 mos; MenACWY-CRM ≥ 2 mos) 
Tetanus, diphtheria, & acellular pertussis1 2  (Tdap: >7 yrs)
Human papillomavirus1 3  (2vHPV: females only; 4vHPV, 
9vHPV: males and females)
Meningococcal B1 1
Pneumococcal polysaccharide5  (PPSV23)
Booster1st doseSee footnote 11
Annual vaccination (LAIV or IIV)  
1 or 2 dosesAnnual vaccination (IIV only) 1 or 2 doses
See footnote 5
(Tdap)
See 
footnote 22
nd dose1st dose
4th dose3rd dose2nd dose1st dose
2-dose series, See footnote 10
3rd or 4th dose, 
See footnote 4
See 
footnote 42
nd dose1st dose
2nd dose1st dose
5th dose4th dose3rd dose2nd dose1st dose
3rd dose2nd dose1st dose
Annual vaccination (LAIV or IIV)  
1 dose only
See footnote 8
See footnote 11
No recommendationRange of recommended ages  
for certain high-risk  groups
Range of recommended 
ages for all children
Range of recommended ages for 
catch-up immunization
Range of recommended ages for non-high-risk groups that may 
receive vaccine, subject to individual clinical decision making
2nd dose1st dose
4th dose3rd dose2nd dose1st dose
(3-dose 
series) 
FIGURE 2. Catch-up immunization schedule for persons aged 4 months through 18 years who start late or who are more than 1 month behind —United States, 2016.
The figure below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child’s age. 
Always use this table in conjunction with Figure 1 and the footnotes that follow.
Children age 4 months through 6 years
Vaccine Minimum Age  for Dose 1
Minimum Interval Between Doses
Dose 1 to Dose 2 Dose 2 to Dose 3 Dose 3 to Dose 4 Dose 4 to Dose 5
Hepatitis B1 Birth 4 weeks
8 weeks 
and at least 16 weeks after first dose. 
Minimum age for the final dose is 24 weeks.
Rotavirus2 6 weeks 4 weeks 4 weeks2
Diphtheria, tetanus, and 
acellular pertussis3 6 weeks 4 weeks 4 weeks 6 months 6 months
3
Haemophilus influenzae 
type b4 6 weeks
4 weeks 
if first dose was administered before the 1st birthday.
8 weeks (as final dose) 
if first dose was administered at age 12 through 14 months.
No further doses needed if first dose was administered at 
age 15 months or older.
4 weeks4 
if current age is younger than 12 months and first dose was administered at younger than age 7 months, and at least 
1 previous dose was PRP-T (ActHib, Pentacel) or unknown.
8 weeks 
and age 12 through 59 months (as final dose for healthy children)4 
•	 if current age is younger than 12 months  
and first dose was administered at age 7 through 11 months (wait until at least 12 months old); 
OR
•	 if current age is 12 through 59 months  
and first dose was administered before the 1st birthday, and second dose administered at younger than 15 
months;  
OR
•	 if both doses were PRP-OMP (PedvaxHIB; Comvax)  
and were administered before the 1st birthday (wait until at least 12 months old).
No further doses needed 
if previous dose was administered at age 15 months or older.
8 weeks (as final dose) 
This dose only necessary for children age 12 through 59 
months who received 3 doses before the 1st birthday.
Pneumococcal5 6 weeks
4 weeks 
if first dose administered before the 1st birthday.
8 weeks (as final dose for healthy children)
if first dose was administered at the 1st birthday or after.
No further doses needed 
for healthy children if first dose administered at age 24 
months or older.
4 weeks 
if current age is younger than 12 months and previous dose given at <7months old.
8 weeks (as final dose for healthy children) 
if previous dose given between 7-11 months (wait until at least 12 months old); 
OR
if current age is 12 months or older and at least 1 dose was given before age 12 months.
No further doses needed for healthy children if previous dose administered at age 24 months or older.
8 weeks (as final dose) 
This dose only necessary for children aged 12 through 
59 months who received 3 doses before age 12 months 
or for children at high risk who received 3 doses at 
any age.
Inactivated poliovirus6 6 weeks 4 weeks6 4 weeks6 6 months6 (minimum age 4 years for final dose).
Measles, mumps, rubella8 12 months 4 weeks
Varicella9 12 months 3 months
Hepatitis A10 12 months 6 months
Meningococcal11  
(Hib-MenCY ≥ 6 weeks; 
MenACWY-D ≥9 mos; 
MenACWY-CRM ≥ 2 mos)
6 weeks 8 weeks11 See footnote 11 See footnote 11
Children and adolescents age 7 through 18 years
Meningococcal11  
(Hib-MenCY ≥ 6 weeks; 
MenACWY-D ≥9 mos; 
MenACWY-CRM ≥ 2 mos)
N/A 8 weeks11 
Tetanus, diphtheria; tetanus, 
diphtheria, and acellular 
pertussis12
7 years12 4 weeks 
4 weeks 
if first dose of DTaP/DT was administered before the 1st birthday. 
6 months (as final dose) 
if first dose of DTaP/DT or Tdap/Td was administered at or after the 1st birthday.
6 months if first dose of DTaP/DT  was administered 
before the 1st birthday.
Human papillomavirus13 9 years Routine dosing intervals are recommended.13
Hepatitis A10
Not  
applicable 
(N/A)
6 months
Hepatitis B1 N/A 4 weeks 8 weeks and at least 16 weeks after first dose.
Inactivated poliovirus6 N/A 4 weeks 4 weeks6 6 months6
Measles, mumps, rubella8 N/A 4 weeks
Varicella9 N/A 3 months if younger than age 13 years. 4 weeks if age 13 years or older.
NOTE: The above recommendations must be read along with the footnotes of this schedule. 
1. Hepatitis B (HepB) vaccine. (Minimum age: birth)
Routine vaccination: 
At birth:
•	 Administer monovalent HepB vaccine to all newborns before hospital 
discharge.
•	 For infants born to hepatitis B surface antigen (HBsAg)-positive 
mothers, administer HepB vaccine and 0.5 mL of hepatitis B immune 
globulin (HBIG) within 12 hours of birth. These infants should be 
tested for HBsAg and antibody to HBsAg (anti-HBs) at age 9 through 
18 months (preferably at the next well-child visit) or 1 to 2 months 
after completion of the HepB series if the series was delayed; CDC 
recently recommended testing occur at age 9 through 12 months; see 
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6439a6.htm.
•	 If mother’s HBsAg status is unknown, within 12 hours of birth 
administer HepB vaccine regardless of birth weight. For infants 
weighing less than 2,000 grams, administer HBIG in addition to HepB 
vaccine within 12 hours of birth. Determine mother’s HBsAg status 
as soon as possible and, if mother is HBsAg-positive, also administer 
HBIG for infants weighing 2,000 grams or more as soon as possible, 
but no later than age 7 days.
Doses following the birth dose:
•	 The second dose should be administered at age 1 or 2 months. 
Monovalent HepB vaccine should be used for doses administered 
before age 6 weeks.
•	 Infants who did not receive a birth dose should receive 3 doses of 
a HepB-containing vaccine on a schedule of 0, 1 to 2 months, and 6 
months starting as soon as feasible. See Figure 2.
•	 Administer the second dose 1 to 2 months after the first dose 
(minimum interval of 4 weeks), administer the third dose at least 8 
weeks after the second dose AND at least 16 weeks after the first 
dose. The final (third or fourth) dose in the HepB vaccine series should 
be administered no earlier than age 24 weeks.
•	 Administration of a total of 4 doses of HepB vaccine is permitted 
when a combination vaccine containing HepB is administered after 
the birth dose. 
Catch-up vaccination:
•	 Unvaccinated persons should complete a 3-dose series.
•	 A 2-dose series (doses separated by at least 4 months) of adult 
formulation Recombivax HB is licensed for use in children aged 11 
through 15 years. 
•	 For other catch-up guidance, see Figure 2.
2. Rotavirus (RV) vaccines. (Minimum age: 6 weeks for both RV1 [Rotarix] 
and RV5 [RotaTeq])
Routine vaccination:
Administer a series of RV vaccine to all infants as follows: 
1. If Rotarix is used, administer a 2-dose series at 2 and 4 months of age. 
2. If RotaTeq is used, administer a 3-dose series at ages 2, 4, and 6 months. 
2. Rotavirus (RV) vaccines (cont’d)
3. If any dose in the series was RotaTeq or vaccine product is unknown 
for any dose in the series, a total of 3 doses of RV vaccine should be 
administered. 
Catch-up vaccination:
•	 The maximum age for the first dose in the series is 14 weeks, 6 days; 
vaccination should not be initiated for infants aged 15 weeks, 0 days 
or older.
•	 The maximum age for the final dose in the series is 8 months, 0 days.
•	 For other catch-up guidance, see Figure 2.
3. Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. 
(Minimum age: 6 weeks. Exception: DTaP-IPV [Kinrix, Quadracel]: 4 
years)
Routine vaccination:
•	 Administer a 5-dose series of DTaP vaccine at ages 2, 4, 6, 15 
through 18 months, and 4 through 6 years.  The fourth dose may be 
administered as early as age 12 months, provided at least 6 months 
have elapsed since the third dose.
•	 Inadvertent administration of 4th DTaP dose early:  If the fourth dose 
of DTaP was administered at least 4 months, but less than 6 months, 
after the third dose of DTaP, it need not be repeated.
Catch-up vaccination:
•	 The fifth dose of DTaP vaccine is not necessary if the fourth dose was 
administered at age 4 years or older.
•	 For other catch-up guidance, see Figure 2.
4. Haemophilus influenzae type b (Hib) conjugate vaccine.  (Minimum 
age:  6 weeks for PRP-T [ACTHIB, DTaP-IPV/Hib (Pentacel) and Hib-
MenCY (MenHibrix)], PRP-OMP [PedvaxHIB or COMVAX], 12 months 
for PRP-T [Hiberix]) 
Routine vaccination:
•	 Administer a 2- or 3-dose Hib vaccine primary series and a booster 
dose (dose 3 or 4 depending on vaccine used in primary series) at age 
12 through 15 months to complete a full Hib vaccine series.
•	 The primary series with ActHIB, MenHibrix, or Pentacel consists of 3 
doses and should be administered at 2, 4, and 6 months of age. The 
primary series with PedvaxHib or COMVAX consists of 2 doses and 
should be administered at 2 and 4 months of age; a dose at age 6 
months is not indicated.
•	 One booster dose (dose 3 or 4 depending on vaccine used in primary 
series) of any Hib vaccine should be administered at age 12 through 
15 months. An exception is Hiberix vaccine. Hiberix should only be 
used for the booster (final) dose in children aged 12 months through 
4 years who have received at least 1 prior dose of Hib-containing 
vaccine.
•	 For recommendations on the use of MenHibrix in patients at increased 
risk for meningococcal disease, please refer to the meningococcal 
vaccine footnotes and also to MMWR February 28, 2014 / 63(RR01);1-
13, available at http://www.cdc.gov/mmwr/PDF/rr/rr6301.pdf.
Catch-up vaccination:
•	 If dose 1 was administered at ages 12 through 14 months, administer 
a second (final) dose at least 8 weeks after dose 1, regardless of Hib 
vaccine used in the primary series.
•	 If both doses were PRP-OMP (PedvaxHIB or COMVAX), and were 
administered before the first birthday, the third (and final) dose 
should be administered at age 12 through 59 months and at least 8 
weeks after the second dose.
•	 If the first dose was administered at age 7 through 11 months, 
administer the second dose at least 4 weeks later and a third (and 
final) dose at age 12 through 15 months or 8 weeks after second dose, 
whichever is later.
•	 If first dose is administered before the first birthday and second dose 
administered at younger than 15 months, a third (and final) dose 
should be administered 8 weeks later.
4. Haemophilus influenzae type b (Hib) conjugate vaccine (cont’d)
•	 For unvaccinated children aged 15 months or older, administer only 
1 dose.
•	 For other catch-up guidance, see Figure 2. For catch-up guidance 
related to MenHibrix, please see the meningococcal vaccine footnotes 
and also MMWR February 28, 2014 / 63(RR01);1-13, available at  
http://www.cdc.gov/mmwr/PDF/rr/rr6301.pdf.
Vaccination of persons with high-risk conditions: 
•	 Children aged 12 through 59 months who are at increased risk for 
Hib disease, including chemotherapy recipients and those with 
anatomic or functional asplenia (including sickle cell disease), human  
immunodeficiency virus (HIV ) infection, immunoglobulin deficiency, 
or early component complement  deficiency, who have received 
either no doses or only 1 dose of Hib vaccine before 12 months of  
age, should receive 2 additional doses of Hib vaccine 8 weeks apart; 
children who received 2 or more  doses of Hib vaccine before 12 
months of age should receive 1 additional dose.
•	 For patients younger than 5 years of age undergoing chemotherapy 
or radiation treatment who received a Hib vaccine dose(s) within 14 
days of starting therapy or during therapy, repeat the dose(s) at least 3 
months following therapy completion.
•	 Recipients of hematopoietic stem cell transplant (HSCT) should be 
revaccinated with a 3-dose regimen of Hib vaccine starting 6 to 12 
months after successful transplant, regardless of vaccination history; 
doses should be administered at least 4 weeks apart.
•	 A single dose of any Hib-containing vaccine should be administered 
to unimmunized* children and adolescents 15 months of age and 
older undergoing an elective splenectomy; if possible, vaccine should 
be administered at least 14 days before procedure.
•	 Hib vaccine is not routinely recommended for patients 5 years or 
older. However, 1 dose of Hib vaccine should be administered to 
unimmunized* persons aged 5 years or older who have anatomic or 
functional asplenia (including sickle cell disease) and unvaccinated 
persons 5 through 18 years of age with HIV infection.
* Patients who have not received a primary series and booster dose or 
at least 1 dose of Hib vaccine after 14 months of age are considered 
unimmunized. 
5. Pneumococcal vaccines. (Minimum age: 6 weeks for PCV13, 2 years 
for PPSV23)
Routine vaccination with PCV13:
•	 Administer a 4-dose series of PCV13 vaccine at ages 2, 4, and 6 
months and at age 12 through 15 months.
•	 For children aged 14 through 59 months who have received an 
age-appropriate series of 7-valent PCV (PCV7), administer a single 
supplemental dose of 13-valent PCV (PCV13). 
Catch-up vaccination with PCV13:
•	 Administer 1 dose of PCV13 to all healthy children aged 24 through 59 
months who are not completely vaccinated for their age.
•	 For other catch-up guidance, see Figure 2. 
Vaccination of persons with high-risk conditions with PCV13 and 
PPSV23:
•	 All recommended PCV13 doses should be administered prior to 
PPSV23 vaccination if possible.
•	 For children 2 through 5 years of age with any of the following 
conditions: chronic heart disease (particularly cyanotic congenital 
heart disease and cardiac failure); chronic lung disease (including 
asthma if treated with high-dose oral corticosteroid therapy); diabetes 
mellitus; cerebrospinal fluid leak; cochlear implant; sickle cell disease 
and other hemoglobinopathies; anatomic or functional asplenia; HIV 
infection; chronic renal failure; nephrotic syndrome; diseases associated 
with treatment with immunosuppressive drugs or radiation therapy, 
including malignant neoplasms, leukemias, lymphomas, and Hodgkin 
disease; solid organ transplantation; or congenital immunodeficiency: 
5. Pneumococcal vaccines (cont’d)
1. Administer 1 dose of PCV13 if any incomplete schedule of 3 doses of 
PCV (PCV7 and/or PCV13) were received previously.
2. Administer 2 doses of PCV13 at least 8 weeks apart if unvaccinated 
or any incomplete schedule of fewer than 3 doses of PCV (PCV7 and/
or PCV13) were received previously.
3. Administer 1 supplemental dose of PCV13 if 4 doses of PCV7 or other 
age-appropriate complete PCV7 series was received previously.
4. The minimum interval between doses of PCV (PCV7 or PCV13) is 
8 weeks.
5. For children with no history of PPSV23 vaccination, administer PPSV23 
at least 8 weeks after the most recent dose of PCV13.
•	 For children aged 6 through 18 years who have cerebrospinal 
fluid leak; cochlear implant; sickle cell disease and other 
hemoglobinopathies; anatomic or functional asplenia; congenital 
or acquired immunodeficiencies; HIV infection; chronic renal failure; 
nephrotic syndrome; diseases associated with treatment with 
immunosuppressive drugs or radiation therapy, including malignant  
neoplasms, leukemias, lymphomas, and Hodgkin disease; generalized 
malignancy; solid organ transplantation; or multiple myeloma:
1. If neither PCV13 nor PPSV23 has been received previously, administer 
1 dose of PCV13 now and 1 dose of PPSV23 at least 8 weeks later.
2. If PCV13 has been received previously but PPSV23 has not, administer 
1 dose of PPSV23 at least 8 weeks after the most recent dose of PCV13.
3. If PPSV23 has been received but PCV13 has not, administer 1 dose of 
PCV13 at least 8 weeks after the most recent dose of PPSV23.
•	 For children aged 6 through 18 years with chronic heart disease 
(particularly cyanotic congenital heart disease and cardiac failure), 
chronic lung disease (including asthma if treated with high-dose oral 
corticosteroid therapy), diabetes mellitus, alcoholism, or chronic liver 
disease, who have not received PPSV23, administer 1 dose of PPSV23. 
If PCV13 has been received previously, then PPSV23 should be 
administered at least 8 weeks after any prior PCV13 dose.
•	 A single revaccination with PPSV23 should be administered 5 
years after the first dose to children with sickle cell disease or other 
hemoglobinopathies; anatomic or functional asplenia; congenital 
or acquired immunodeficiencies; HIV infection; chronic renal failure; 
nephrotic syndrome; diseases associated with treatment with 
immunosuppressive drugs or radiation therapy, including malignant 
neoplasms, leukemias, lymphomas, and Hodgkin disease; generalized 
malignancy; solid organ transplantation; or multiple myeloma.
6. Inactivated poliovirus vaccine (IPV). (Minimum age: 6 weeks)
Routine vaccination:
•	 Administer a 4-dose series of IPV at ages 2, 4, 6 through 18 months, and 4 
through 6 years. The final dose in the series should be administered on or 
after the fourth birthday and at least 6 months after the previous dose.
6. Inactivated poliovirus vaccine (cont’d)
Catch-up vaccination:
•	 In the first 6 months of life, minimum age and minimum intervals are 
only recommended if the person is at risk of imminent exposure to 
circulating poliovirus (i.e., travel to a polio-endemic region or during 
an outbreak).
•	 If 4 or more doses are administered before age 4 years, an additional 
dose should be administered at age 4 through 6 years and at least 6 
months after the previous dose.
•	 A fourth dose is not necessary if the third dose was administered at 
age 4 years or older and at least 6 months after the previous dose.
•	 If both OPV and IPV were administered as part of a series, a total of 4 
doses should be administered, regardless of the child’s current age. If 
only OPV were administered, and all doses were given prior to 4 years 
of age, one dose of IPV should be given at 4 years or older, at least 4 
weeks after the last OPV dose.
•	 IPV is not routinely recommended for U.S. residents aged 18 years 
or older.
•	 For other catch-up guidance, see Figure 2.
7. Influenza vaccines. (Minimum age: 6 months for inactivated influenza 
vaccine [IIV], 2 years for live, attenuated influenza vaccine [LAIV]) 
Routine vaccination:
•	 Administer influenza vaccine annually to all children beginning 
at age 6 months. For most healthy, nonpregnant persons aged 2 
through 49 years, either LAIV or IIV may be used. However, LAIV 
should NOT be administered to some persons, including 1) persons 
who have experienced severe allergic reactions to LAIV, any of its 
components, or to a previous dose of any other influenza vaccine; 2) 
children 2 through 17 years receiving aspirin or aspirin-containing 
products; 3) persons who are allergic to eggs; 4) pregnant women; 5) 
immunosuppressed persons; 6) children 2 through 4 years of age with 
asthma or who had wheezing in the past 12 months; or 7) persons 
who have taken influenza antiviral medications in the previous 48 
hours. For all other contraindications and precautions to use of LAIV, 
see MMWR August 7, 2015 / 64(30):818-25 available at http://www.
cdc.gov/mmwr/pdf/wk/mm6430.pdf.
For children aged 6 months through 8 years:
•	 For the 2015-16 season, administer 2 doses (separated by at least 4 
weeks) to children who are receiving influenza vaccine for the first 
time. Some children in this age group who have been vaccinated 
previously will also need 2 doses. For additional guidance, 
follow dosing guidelines in the 2015-16 ACIP influenza vaccine 
recommendations, MMWR August 7, 2015 / 64(30):818-25, available at 
http://www.cdc.gov/mmwr/pdf/wk/mm6430.pdf.
•	 For the 2016-17 season, follow dosing guidelines in the 2016 ACIP 
influenza vaccine recommendations.  
For persons aged 9 years and older:
•	 Administer 1 dose.
8. Measles, mumps, and rubella (MMR) vaccine. (Minimum age: 12 
months for routine vaccination)
Routine vaccination:
•	 Administer a 2-dose series of MMR vaccine at ages 12 through 15 months 
and 4 through 6 years. The second dose may be administered before age 
4 years, provided at least 4 weeks have elapsed since the first dose.
•	 Administer 1 dose of MMR vaccine to infants aged 6 through 11 months 
before departure from the United States for international travel. These 
children should be revaccinated with 2 doses of MMR vaccine, the first 
at age 12 through 15 months (12 months if the child remains in an area 
where disease risk is high), and the second dose at least 4 weeks later.
•	 Administer 2 doses of MMR vaccine to children aged 12 months and 
older before departure from the United States for international travel. 
The first dose should be administered on or after age 12 months and the 
second dose at least 4 weeks later.
8. Measles, mumps, and rubella (MMR) vaccine (cont’d)
Catch-up vaccination:
•	 Ensure that all school-aged children and adolescents have had 2 
doses of MMR vaccine; the minimum interval between the 2 doses is 
4 weeks.  
9. Varicella (VAR) vaccine. (Minimum age: 12 months) 
Routine vaccination:
•	 Administer a 2-dose series of VAR vaccine at ages 12 through 15 
months and 4 through 6 years. The second dose may be administered 
before age 4 years, provided at least 3 months have elapsed since the 
first dose. If the second dose was administered at least 4 weeks after 
the first dose, it can be accepted as valid.
Catch-up vaccination:
•	 Ensure that all persons aged 7 through 18 years without evidence 
of immunity (see MMWR 2007 / 56 [No. RR-4], available at http://
www.cdc.gov/mmwr/pdf/rr/rr5604.pdf ) have 2 doses of varicella 
vaccine.  For children aged 7 through 12 years, the recommended 
minimum interval between doses is 3 months (if the second dose was 
administered at least 4 weeks after the first dose, it can be accepted 
as valid); for persons aged 13 years and older, the minimum interval 
between doses is 4 weeks.
10. Hepatitis A (HepA) vaccine. (Minimum age: 12 months)
Routine vaccination:
•	 Initiate the 2-dose HepA vaccine series at 12 through 23 months; separate 
the 2 doses by 6 to 18 months.
•	 Children who have received 1 dose of HepA vaccine before age 24 
months should receive a second dose 6 to 18 months after the first dose.
•	 For any person aged 2 years and older who has not already received 
the HepA vaccine series, 2 doses of HepA vaccine separated by 6 to 
18 months may be administered if immunity against hepatitis A virus 
infection is desired. 
Catch-up vaccination:
•	 The minimum interval between the 2 doses is 6 months. 
Special populations: 
•	 Administer 2 doses of HepA vaccine at least 6 months apart to 
previously unvaccinated persons who live in areas where vaccination 
programs target older children, or who are at increased risk for 
infection. This includes persons traveling to or working in countries 
that have high or intermediate endemicity of infection; men having 
sex with men; users of injection and non-injection illicit drugs; 
persons who work with HAV-infected primates or with HAV in a 
research laboratory; persons with clotting-factor disorders; persons 
with chronic liver disease; and persons who anticipate close personal 
contact (e.g., household or regular babysitting) with an international 
adoptee during the first 60 days after arrival in the United States from 
a country with high or intermediate endemicity. The first dose should 
be administered as soon as the adoption is planned, ideally 2 or more 
weeks before the arrival of the adoptee.
11. Meningococcal vaccines. (Minimum age: 6 weeks for Hib-MenCY 
[MenHibrix], 9 months for MenACWY-D [Menactra], 2 months for 
MenACWY-CRM [Menveo], 10 years for serogroup B meningococcal 
[MenB] vaccines: MenB-4C [Bexsero] and MenB-FHbp [Trumenba])
Routine vaccination:
•	 Administer a single dose of Menactra or Menveo vaccine at age 11 
through 12 years, with a booster dose at age 16 years.
•	 Adolescents aged 11 through 18 years with human immunodeficiency 
virus (HIV ) infection should receive a 2-dose primary series of 
Menactra or Menveo with at least 8 weeks between doses.
•	 For children aged 2 months through 18 years with high-risk 
conditions, see below.
Catch-up vaccination:
•	 Administer Menactra or Menveo vaccine at age 13 through 18 years if not 
previously vaccinated.
11. Meningococcal vaccines (cont’d)
•	 If the first dose is administered at age 13 through 15 years, a booster 
dose should be administered at age 16 through 18 years with a minimum 
interval of at least 8 weeks between doses.
•	 If the first dose is administered at age 16 years or older, a booster dose is 
not needed.
•	 For other catch-up guidance, see Figure 2.
Clinical discretion:
•	 Young adults aged 16 through 23 years (preferred age range is 16 
through 18 years) may be vaccinated with either a 2-dose series of 
Bexsero or a 3-dose series of Trumenba vaccine to provide short-term 
protection against most strains of serogroup B meningococcal disease. 
The two MenB vaccines are not interchangeable; the same vaccine 
product must be used for all doses.
Vaccination of persons with high-risk conditions and other persons at 
increased risk of disease: 
Children with anatomic or functional asplenia (including sickle cell 
disease) 
Meningococcal conjugate ACWY vaccines:
1. Menveo  
o Children who initiate vaccination at 8 weeks: Administer doses at 2, 4, 
6, and 12 months of age.
o Unvaccinated children who initiate vaccination at 7 through 23 months: 
Administer 2 doses, with the second dose at least 12 weeks after the 
first dose AND after the first birthday.
o Children 24 months and older who have not received a complete series: 
Administer 2 primary doses at least 8 weeks apart.
2. MenHibrix
o Children who initiate vaccination at 6 weeks: Administer doses at 2, 4, 
6, and 12 through 15 months of age.
o If the first dose of MenHibrix is given at or after 12 months of age, 
a total of 2 doses should be given at least 8 weeks apart to ensure 
protection against serogroups C and Y meningococcal disease.
3. Menactra
o Children 24 months and older who have not received a complete series: 
Administer 2 primary doses at least 8 weeks apart. If Menactra is 
administered to a child with asplenia (including sickle cell disease), 
do not administer Menactra until 2 years of age and at least 4 weeks 
after the completion of all PCV13 doses.
Meningococcal B vaccines:
1. Bexsero or Trumenba
o Persons 10 years or older who have not received a complete series. 
Administer a 2-dose series of Bexsero, at least 1 month apart. Or a 
3-dose series of Trumenba, with the second dose at least 2 months 
after the first and the third dose at least 6 months after the first. The 
two MenB vaccines are not interchangeable; the same vaccine product 
must be used for all doses.
11. Meningococcal vaccines (cont’d)
Children with persistent complement component deficiency (includes 
persons with inherited or chronic deficiencies in C3, C5-9, properidin, factor 
D, factor H, or taking eculizumab (Soliriis®):
Meningococcal conjugate ACWY vaccines:
1. Menveo
o Children who initiate vaccination at 8 weeks: Administer doses at 2, 4, 
6, and 12 months of age.
o Unvaccinated children who initiate vaccination at 7 through 23 
months: Administer 2 doses, with the second dose at least 12 weeks 
after the first dose AND after the first birthday.
o Children 24 months and older who have not received a complete series: 
Administer 2 primary doses at least 8 weeks apart. 
2. MenHibrix
o Children who initiate vaccination at 6 weeks: Administer doses at 2, 
4, 6, and 12 through 15 months of age.
o If the first dose of MenHibrix is given at or after 12 months of age, 
a total of 2 doses should be given at least 8 weeks apart to ensure 
protection against serogroups C and Y meningococcal disease.
3. Menactra
o Children 9 through 23 months: Administer 2 primary doses at least 
12 weeks apart.
o Children 24 months and older who have not received a complete series: 
Administer 2 primary doses at least 8 weeks apart.
Meningococcal B vaccines:
1. Bexsero or Trumenba
o Persons 10 years or older who have not received a complete series. 
Administer a 2-dose series of Bexsero, at least 1 month apart. Or a 
3-dose series of Trumenba, with the second dose at least 2 months 
after the first and the third dose at least 6 months after the first. 
The two MenB vaccines are not interchangeable; the same vaccine 
product must be used for all doses.
For children who travel to or reside in countries in which meningococcal 
disease is hyperendemic or epidemic, including countries in the African 
meningitis belt or the Hajj: 
•	 administer an age-appropriate formulation and series of Menactra or 
Menveo for protection against serogroups A and W meningococcal 
disease. Prior receipt of MenHibrix is not sufficient for children 
traveling to the meningitis belt or the Hajj because it does not contain 
serogroups A or W.
For children at risk during a community outbreak attributable to a vaccine 
serogroup:
•	 administer or complete an age- and formulation-appropriate series of 
MenHibrix, Menactra, Menveo, Bexsero, or Trumenba. 
For booster doses among persons with high-risk conditions, refer to 
MMWR 2013 / 62(RR02);1-22, available at http://www.cdc.gov/mmwr/
preview/mmwrhtml/rr6202a1.htm.
For other catch-up recommendations for these persons, and complete 
information on use of meningococcal vaccines, including guidance 
related to vaccination of persons at increased risk of infection, see MMWR 
March 22, 2013 / 62(RR02);1-22, and MMWR October 23, 2015 / 64(41); 
1171-1176 available at  http://www.cdc.gov/mmwr/pdf/rr/rr6202.pdf, 
and http://www.cdc.gov/mmwr/pdf/wk/mm6441.pdf.
12. Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine. 
(Minimum age: 10 years for both Boostrix and Adacel)
Routine vaccination: 
•	 Administer 1 dose of Tdap vaccine to all adolescents aged 11 through 
12 years.
•	 Tdap may be administered regardless of the interval since the last 
tetanus and diphtheria toxoid-containing vaccine.
•	 Administer 1 dose of Tdap vaccine to pregnant adolescents during each 
pregnancy (preferred during 27 through 36 weeks gestation) regardless 
of time since prior Td or Tdap vaccination. 
12. Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine 
(cont’d)
Catch-up vaccination:
•	 Persons aged 7 years and older who are not fully immunized with DTaP 
vaccine should receive Tdap vaccine as 1 (preferably the first) dose in 
the catch-up series; if additional doses are needed, use Td vaccine. For 
children 7 through 10 years who receive a dose of Tdap as part of the 
catch-up series, an adolescent Tdap vaccine dose at age 11 through 12 
years should NOT be administered. Td should be administered instead 
10 years after the Tdap dose.
•	 Persons aged 11 through 18 years who have not received Tdap 
vaccine should receive a dose followed by tetanus and diphtheria 
toxoids (Td) booster doses every 10 years thereafter.
•	 Inadvertent doses of DTaP vaccine:
 - If administered inadvertently to a child aged 7 through 10 years 
may count as part of the catch-up series. This dose may count as the 
adolescent Tdap dose, or the child can later receive a Tdap booster 
dose at age 11 through 12 years.
 - If administered inadvertently to an adolescent aged 11 through 18 
years, the dose should be counted as the adolescent Tdap booster. 
•	 For other catch-up guidance, see Figure 2.
13. Human papillomavirus (HPV) vaccines. (Minimum age: 9 years for 
2vHPV [Cervarix], 4vHPV [Gardasil] and 9vHPV [Gardasil 9])
Routine vaccination:
•	 Administer a 3-dose series of HPV vaccine on a schedule of 0, 1-2, and 
6 months to all adolescents aged 11 through 12 years. 9vHPV, 4vHPV 
or 2vHPV may be used for females, and only 9vHPV or 4vHPV may be 
used for males.
•	 The vaccine series may be started at age 9 years.
•	 Administer the second dose 1 to 2 months after the first dose 
(minimum interval of 4 weeks); administer the third dose 16 weeks 
after the second dose (minimum interval of 12 weeks) and  24 weeks 
after the first  dose.
•	 Administer HPV vaccine beginning at age 9 years to children and 
youth with any history of sexual abuse or assault who have not 
initiated or completed the 3-dose series.
Catch-up vaccination:
•	 Administer the vaccine series to females (2vHPV or 4vHPV or 9vHPV) 
and males (4vHPV or 9vHPV) at age 13 through 18 years if not 
previously vaccinated.
•	 Use recommended routine dosing intervals (see Routine vaccination 
above) for vaccine series catch-up. 
Footnotes — Recommended immunization schedule for persons aged 0 through 18 years—United States, 2016 
For further guidance on the use of the vaccines mentioned below, see: http://www.cdc.gov/vaccines/hcp/acip-recs/index.html.  
For vaccine recommendations for persons 19 years of age and older, see the Adult Immunization Schedule.
Additional information
•	 For contraindications and precautions to use of a vaccine and for additional information regarding that vaccine, vaccination providers should consult the relevant ACIP statement available online at  
http://www.cdc.gov/vaccines/hcp/acip-recs/index.html. 
•	 For purposes of calculating intervals between doses, 4 weeks = 28 days. Intervals of 4 months or greater are determined by calendar months.
•	 Vaccine doses administered 4 days or less before the minimum interval are considered valid. Doses of any vaccine administered ≥5 days earlier than the minimum interval or minimum age should not be counted as valid doses 
and should be repeated as age-appropriate. The repeat dose should be spaced after the invalid dose by the recommended minimum interval. For further details, see MMWR, General Recommendations on Immunization and 
Reports / Vol. 60 / No. 2; Table 1. Recommended and minimum ages and intervals between vaccine doses available online at http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf.
•	 Information on travel vaccine requirements and recommendations is available at http://wwwnc.cdc.gov/travel/destinations/list.
•	 For vaccination of persons with primary and secondary immunodeficiencies, see Table 13, “Vaccination of persons with primary and secondary immunodeficiencies,” in General Recommendations on Immunization (ACIP), available 
at http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf.; and American Academy of Pediatrics. “Immunization in Special Clinical Circumstances,” in Kimberlin DW, Brady MT, Jackson MA, Long SS eds. Red Book: 2015 report of the 
Committee on Infectious Diseases. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics.
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